Even once you have funding secured, the regulatory approval process is long and requires hundreds of pages of documentation, reporting, and compliance. Then you have to get insurance to cover it, which can require a procedural code being generated for it by the AMA and requires convincing insurers it's worth it, particularly Medicare in the US which other insurers take their cues from. And even once a procedure is approved and a patient can get it paid for, you still have inertia from human physicians who have been trained to perform certain kinds of treatments and not others.
But to answer your question, that uterus transplantation was (a) an experimental therapy overseen by an IRB to treat a diagnosed medical condition, (b) almost certainly funded by grants acquired by Baylor and not insurance, and (c) the therapy is still in clinical testing and not available to indicated patients today in 2025, 8 years later, unless they are part of a clinical study, which demonstrates how lengthy the process is.